natgillin/translations-raw huggingface dataset:
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Ako primijetite bilo kakve simptome infekcije ili druge simptome, kao što su slabost mišića, slabost koja počinje u rukama i stopalima te se pomiče prema trupu tijela, osjećaj lupanja srca, nesvjesno drhtanje ili hiperaktivnost, molimo da odmah obavijestite liječnika kako bi proveo potrebno liječenje.
Tipranavir AUC over a 12 hour dosing interval averaged 851 ± 309 µM•h (CL=1.15 l/h) for female patients and 710 ± 207 µM•h (CL=1.27 l/h) for male patients.
Tijekom 12-satnog intervala, AUC tipranavira iznosio je 851 ± 309 µM•h (CL=1,15 l/h) u žena i 710 ± 207 µM•h (CL=1,27 l/h) u muškaraca.
INFORMATION IN BRAILLE Aptivus 250 mg
16. PODACI NA BRAILLEOVOM PISMU Aptivus 250 mg
Treatment response* at week 48 (pooled studies RESIST-1 and RESIST-2 in treatmentexperienced patients)
Terapijski odgovor* u 48. tjednu (združeni rezultati RESIST-1 i RESIST-2 u bolesnika s iskustvom liječenja)
Excipients with known effect: Each soft capsule contains 100.0 mg ethanol, 455.0 mg macrogolglycerol ricinoleate and 12.6 mg sorbitol For the full list of excipients, see section 6.1.
Pomoćne tvari s poznatim učinkom: Jedna meka kapsula sadrži 100,0 mg etanola, 455,0 mg makrogolglicerolricinoleata i 12,6 mg sorbitola
In general, caution should be exercised in the administration and monitoring of Aptivus in older people reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy (see section 4.4).
Općenito, potreban je oprez u primjeni i praćenju Aptivusa u starijih osoba zbog veće učestalosti smanjene funkcije jetre, bubrega ili srca, komorbiditeta ili druge terapije (vidjeti dio 4.4).
However, it is unknown whether the combination of tipranavir with ritonavir might cause a larger increase in trazodone exposure.
Međutim, nije poznato može li kombinacija tipranavira s ritonavirom izazvati veće povećanje izlaganja trazodonu.
The effect of tipranavir with low dose of ritonavir on the QTcF interval was measured in a study in which 81 healthy subjects received the following treatments twice daily for 2.5 days: tipranavir/ritonavir (500/200 mg), tipranavir/ritonavir at a supra-therapeutic dose (750/200 mg), and placebo/ritonavir (-/200 mg).
Učinak tipranavira s niskom dozom ritonavira na QTcF interval bio je ispitivan u 81 zdravog dobrovoljca koji su terapiju primali dvaput dnevno u trajanju 2,5 dana: tipranavir/ritonavir (500/200 mg), tipranavir/ritonavir u supraterapijskim dozama (750/200 mg) i placebo/ritonavir (-/200 mg).
Your child must not breast-feed the baby because it is possible that the baby can become HIV-infected through the breast milk.
Vaša kćer ne smije dojiti dijete jer postoji mogućnost prijenosa HIV-a na bebu putem majčinog mlijeka.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Bolesnike je potrebno uputiti da se jave liječniku u slučaju bolova u zglobovima, ukočenosti zglobova, ili problema s kretanjem.
However a decrease of colchicine concentrations cannot be excluded since both tipranavir and ritonavir exhibit inducing potential towards CYP3A and P-gp.
Međutim, ne može se isključiti smanjenje koncentracija kolhicina s obzirom da i tipranavir i ritonavir pokazuju potencijal za induciranje CYP3A i P-gp.
- abacavir and zidovudine.
- abakavir i zidovudin.
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your child's doctor immediately to seek necessary treatment.
Ako primijetite bilo kakve simptome infekcije ili druge simptome, kao što su slabost mišića, slabost koja počinje u rukama i stopalima te se pomiče prema trupu tijela, osjećaj lupanja srca, nesvjesno drhtanje ili hiperaktivnost, molimo da odmah obavijestite djetetovog liječnika kako bi proveo potrebno liječenje.
If you take other medicines at the same time as Aptivus and ritonavir, this can strengthen or weaken the effect of the medicines.
Ako istodobno s Aptivusom i ritonavirom uzimate druge lijekove, to može ojačati ili oslabiti učinak lijekova.
The effects of sildenafil and vardenafil are likely to be increased if you take them with Aptivus.
Učinci sildenafila i vardenafila će se vjerojatno povećati ako ih uzimate s Aptivusom.
In case of concomitant administration of emtricitabine and Aptivus/ritonavir, renal function should be evaluated before initiating the co-administration.
U slučaju istodobne primjene emtricitabina i Aptivusa/ritonavira, potrebno je procijeniti bubrežnu funkciju prije početka takve primjene.
Failure to correctly co-administer tipranavir with ritonavir will result in reduced plasma levels of tipranavir that may be insufficient to achieve the desired antiviral effect.
Neispravna provedba istodobne primjene tipranavira s ritonavirom rezultirat će sniženim razinama tipranavira u plazmi koje mogu biti nedostatne za postizanje željenog antivirusnog učinka.
Your doctor will only prescribe you abacavir and zidovudine if you are unable to take other NRTIs.
Liječnik će propisati abakavir i zidovudin samo ako ne možete uzimati druge NRTI.
Frequencies of marked clinical laboratory abnormalities (Grade 3 or 4) reported in at least 2% of patients in the tipranavir with ritonavir arms in the phase III clinical studies (RESIST-1 and RESIST2) after 48-weeks were increased ASAT (6.1%), increased ALAT (9.7%), increased amylase (6.0%), increased cholesterol (4.2%), increased triglycerides (24.9%), and decreased white blood cell count
Izražene kliničke laboratorijske abnormalnosti (stupanj 3 ili 4), prijavljene u najmanje 2% bolesnika liječenih tipranavirom s ritonavirom u kliničkim ispitivanjima faze III (RESIST-1 i RESIST-2) nakon 48 tjedana bile su: povišenje AST (6,1%), povišenje ALT (9,7%), povišenje amilaza (6,0%), povišeni kolesterol (4,2%), povišeni trigliceridi (24,9%) i smanjeni broj leukocita (5,7%).
Administer Aptivus oral solution immediately.
Odmah primijenite Aptivus oralnu otopinu.
If you take aluminium- and magnesium-based antacid (used to treat dyspepsia/gastrooesophageal reflux), the time interval between Aptivus and antacid should be at least two hours.
Ako uzimate antacide na bazi aluminija i magnezija (primjenjuju se u liječenju dispepsije/gastroezofagealnog refluksa) vremenski razmak između Aptivusa i antacida mora biti najmanje dva sata.
- didanosine: If your child is taking didanosine enteric coated tablets, they should take them at least two hours before or after Aptivus.
- didanozin: Iako Vaše dijete uzima želučano otporne tablete didanozina, potrebno je primjenjivati ih najmanje dva sata prije ili nakon Aptivusa.
In a
A.
There was no pattern for the bleeding events and no difference between treatment groups in coagulation parameters.
Nije uočen neki poseban obrazac krvarenja i nije bilo razlika u rezultatima testova koagulacije između skupina.
Higher doses of carbamazepine (> 200 mg) may result in even larger decreases in tipranavir plasma concentrations (see section 4.4).
Više doze karbamazepina (> 200 mg) mogu rezultirati čak i većim smanjenjima koncentracija u plazmi (vidjeti dio
The mean half-life was 5.5 (females) or 6.0 hours (males).
Prosječni poluvijek eliminacije iznosio je 5,5 sati u žena i 6 sati u muškaraca.
Your child should not use Aptivusif they have never received antiretroviral therapy or have other antiretroviral options available.
Vaše dijete ne smije primjenjivati Aptivus ako nikada nije primalo antiretrovirusnu terapiju ili su mu dostupne druge opcije antiretrovirusnog liječenja.
Increased CPK, myalgia, myositis and, rarely, rhabdomyolysis, have been reported with protease inhibitors, particularly in combination with nucleoside reverse transcriptase inhibitors.
Povišena kreatin fosfokinaza (CPK), mialgija, miozitis i, rijetko, rabdomioliza prijavljeni su uz inhibitore proteaze, osobito u kombinaciji s nukleozidnim inhibitorima reverzne transkriptaze.
- The other ingredients are macrogolglycerol ricinoleate, ethanol (alcohol), mono/diglycerides of caprylic/capric acid, propylene glycol, purified water, trometamol and propyl gallate.
- Drugi sastojci su makrogolglicerolricinoleat, etanol (alkohol), mono/digliceridi kaprilatne/kaprinske kiseline, propilenglikol, pročišćena voda, trometamol i propilgalat.
The concurrent administration of tipranavir and low dose ritonavir may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Istodobna primjena s tipranavirom uz nisku dozu ritonavira može rezultirati povećanim rizikom od kardiovaskularnih nuspojava salmeterola, uključujući QT produljenje, palpitacije i sinusnu tahikardiju.
If your child has: - high liver function tests results - hepatitis B or C infection your child is at increased risk of severe and potentially fatal liver damage while taking Aptivus.
Ako imate sljedeće: - visoke vrijednosti rezultata testiranja funkcije jetre - infekciju hepatitisom B ili C pod povećanim ste rizikom od teškog i potencijalno fatalnog oštećenja jetre tijekom primjene Aptivusa.
Aptivus contains the active substance tipranavir.
Aptivus sadrži djelatnu tvar tipranavir.
Group O and HIV-2 isolates have reduced susceptibility in vitro to tipranavir with EC50 values ranging from 0.164-1 µM and 0.233-0.522 µM, respectively.
Izolati HIV-1 skupine O i HIV-2 izolati manje su osjetljivi na tipranavir in vitro, s rasponom EC50 od 0,164-1 µM i 0,233-0,522 µM.
You should inform your doctor as soon as possible if you notice the signs or symptoms of hepatitis: - fever - malaise (feeling generally unwell) - nausea (upset stomach) - vomiting - abdominal pain - tiredness
Potrebno je obavijestiti liječnika što je prije moguće ako primijetite znakove ili simptome hepatitisa: - vrućica - malaksalost (opći osjećaj lošeg stanja) - mučnina - povraćanje - abdominalna bol - umor
Therefore, tipranavir with ritonavir should not be used in treatment-naïve patients (see section 4.2).
Stoga se tipranavir s ritonavirom ne smije primjenjivati u liječenju prethodno neliječenih bolesnika (vidjeti dio 4.2).
Due to reduction in the levels of the active metabolite norbuprenorphine, co-administration of Aptivus, coadministered with low dose ritonavir, and buprenorphine/naloxone may result in decreased clinical efficacy of buprenorphine.
Zbog smanjenja razina aktivnog metabolita norbuprenorfina, istodobna primjena Aptivusa s niskom dozom ritonavira i buprenorfin/naloksona može rezultirati smanjenom kliničkom učinkovitošću buprenorfina.
Each ml contains 100 mg tipranavir.
Svaki ml sadrži 100 mg tipranavira.
The clinical relevance of the reduced loperamide plasma concentration is unknown.
Klinički značaj smanjenih koncentracija loperamida u plazmi nije poznat.
Baseline % CD4+ cells Median (Min - Max)
Početni % CD4+ stanica medijan (min.-maks.)
Also the use of the alpha-1 adrenoceptor antagonist alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension.
Također primjena antagonista alfa-1 adrenergičnih receptora alfuzosina i sildenafila kada se primjenjuju u liječenju plućne arterijske hipertenzije.
Aptivus also contains macrogolglycerol ricinoleate which may cause stomach upset and diarrhoea.
Aptivus također sadrži makrogolglicerolricinoleat koji može uzrokovati želučane tegobe i proljev.
In Phase II and III clinical trials, 276 patients with on-treatment genotypes have demonstrated that the predominant emerging mutations with tipranavir treatment are L33F/I/V, V82T/L and I84V.
Analiza 276 bolesnika iz ispitivanja faze II i faze III s genotipovima određenim tijekom liječenja pokazala je da su dominantne mutacije koje nastaju tijekom liječenja tipranavirom L33F/I/V, V82T/L i I84V.
Potential interactions with renal transporters cannot be fully excluded.
Ne mogu se u potpunosti isključiti potencijalne interakcije s bubrežnim prijenosnicima.
Before starting treatment, your child's doctor will have taken blood samples to test the resistance of your child's HIV.
Prije početka liječenja, djetetov liječnik će uputiti uzorke krvi Vašeg djeteta na testiranje na otpornost njegovog HIV-a.
Co-administrationof Aptivus/ritonavir with sildenafil, when used to treat pulmonary arterial hypertension, is contraindicated.
Istodobna primjena Aptivusa/ritonavira sa sildenafilom kada se koristi u liječenju plućne arterijske hipertenzije je kontraindicirana.
Dose Aptivus (mg)
Doza Aptivusa (mg)
- The other ingredients are macrogol, vitamin E polyethylene glycol succinate, purified water,
- Drugi sastojci su makrogol, vitamin E polietilenglikolsukcinat, pročišćena voda, propilenglikol,
The influence of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment on the multiple dose pharmacokinetics of either tipranavir or ritonavir has so far not been investigated.
Utjecaj umjerenog (Child-Pugh B) ili teškog (Child-Pugh C) oštećenja jetre na farmakokinetiku višestrukih doza do danas nije ispitan.
Tipranavir Cmax ↓ 25% Tipranavir AUC ↓ 27% Mechanism unknown
Tipranavir Cmax ↓ 25% Tipranavir AUC ↓ 27% Mehanizam nepoznat
Co-administration of Aptivus and agents that induce CYP3A and/or P-gp may decrease tipranavir concentrations and reduce its therapeutic effect (see list and details of considered agents, below).
Istodobna primjena Aptivusa i lijekova koji induciraju CYP3A i/ili P-gp može smanjiti koncentracije tipranavira te smanjiti njegov terapijski učinak (vidjeti popis relevantnih lijekova u nastavku).
No data are available for H2receptor antagonists in combination with tipranavir and low dose ritonavir.
Nema dostupnih podataka o anatgonistima H2-receptora u kombinaciji s tipranavirom i niskom dozom ritonavira.
In a study conducted in rats with tipranavir at systemic exposure levels (AUC) equivalent to human exposure at the recommended clinical dose, no adverse effects on mating or fertility were observed.
U štakora, pri sistemskoj izloženosti (AUC) koja je ekvivalentna izloženosti u ljudi pri preporučenoj kliničkoj dozi, nisu primijećeni učinci na parenje i plodnost.
The concomitant use of Aptivus, co-administered with low dose ritonavir, with zidovudine or abacavir, results in a significant decrease in plasma concentration of these nucleoside reverse transcriptase inhibitors (NRTIs).
Istodobna primjena Aptivusa s niskom dozom ritonavira, sa zidovudinom ili abakavirom, rezultira značajnim smanjenjem koncentracija ovih nukleozidnih inhibitora reverzne transkriptaze (NRTI) u plazmi.
At 48-weeks, a higher proportion of patients receiving tipranavir withritonavir achieved a treatment response in comparison to the comparator protease inhibitor/ritonavir for nearly all of the possible combinations of genotypic resistance mutations (see table below).
U 48 tjedana, veći je broj bolesnika na tipranaviru s ritonavirom postigao reakciju na liječenje u usporedbi s kontrolnom skupinom liječenom inhibitorom proteaze s ritonavirom za gotovo sve moguće kombinacije genotipskih mutacija povezanih s rezistencijom (vidjeti tablicu u nastavku).
First-dose tipranavir/r Digoxin Cmax ↑ 93% Digoxin AUC ↑ 91%
Prva doza tipranavira/r Digoksin Cmax ↑ 93% Digoksin AUC ↑ 91%
Saquinavir/ritonavir 600/100 mg QD
Sakvinavir/ritonavir 600/100 mg QD
However, since the renal clearance of tipranavir is negligible, a decrease in total body clearance is not expected in patients with renal impairment.
Međutim, s obzirom da je renalni klirens tipranavira zanemariv, ne očekuje se smanjenje ukupnog tjelesnog klirensa u bolesnika s oštećenjem bubrega.
Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency (see sections 4.4 and
Bolesnice koje primjenjuju estrogene kao nadomjesnu hormonsku terapiju moraju se klinički pratiti radi znakova deficijencije estrogena (vidjeti dijelove 4.4 i 4.6).
In the RESIST trials, the risk of rash was similar between tipranavir with ritonavir and comparator arms (16.3% vs. 12.5%, respectively; see section 4.4).
U RESIST ispitivanjima rizik od osipa bio je sličan između skupine koja je dobivala tipranavir s ritonavirom i kontrolne skupine (16,3% naspram 12,5%, vidjeti dio 4.4).
After Week 8, patients in the comparator arm who met the protocol defined criteria of initial lack of virologic response had the option of discontinuing treatment and switching over to tipranavir with ritonavir in a separate roll-over study.
Nakon 8. tjedna, bolesnici u kontrolnoj skupini koji su udovoljili kriterijima za početni izostanak virusne reakcije, imali su mogućnost prekida liječenja te prijelaza na tipranavir s ritonavirom u posebnoj studiji.
Black printing ink Propylene glycol Black iron oxide (E172) Polyvinyl acetate phthalate Macrogol
Crna tinta za označavanje propilenglikol željezov oksid, crni (E172) poli(vinilacetat) ftalat makrogol amonijev hidroksid
Assessment of adverse reactions from HIV-1 clinical study data is based on experience in all Phase II and III trials in adults treated with the 500 mg tipranavir with 200 mg ritonavir dose twice daily (n=1397) and are listed below by system organ class and frequency according to the following categories:
Podaci o nuspojavama uočenim u kliničkim ispitivanjima odnose se na sva ispitivanja faze II i faze III u odraslih bolesnika s HIV-1 infekcijom koji su dobivali 500 mg tipranavira uz 200 mg ritonavira dvaput dnevno (n=1397) i navedene su prema organskim sustavima i učestalosti, prema ovim kategorijama:
Proton pump inhibitors (PPIs) Omeprazole 40 mg QD Omeprazole Cmax ↓ 73%
Inhibitori protonske pumpe (IPP) Omeprazol 40 mg QD Omeprazol Cmax ↓ 73%
Buprenorphine/Naloxone Buprenorphine ↔ Norbuprenorphine AUC  79% Norbuprenorphine Cmax  80% Norbuprenorphine Cmin  80%
Buprenorfin/nalokson Buprenorfin ↔ Norbuprenorfin AUC  79% Norbuprenorfin Cmax  80% Norbuprenorfin Cmin  80%
Based on the known interaction of voriconazole with low dose ritonavir (see voriconazole SmPC) the co-administration of tipranavir/r and voriconazole should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
Temeljem poznatih interakcija vorikonazola s niskom dozom ritonavira (vidjeti Sažetak opisa svojstava lijeka za vorikonazol), potrebno je izbjegavati istodobnu primjenu tipranavira/r i vorikonazola, osim ako procijenjeni odnos koristi i rizika za bolesnika ne opravdava primjenu vorikonazola.
Your child's doctor will only prescribe them abacavir and zidovudine if they are unable to take other NRTIs.
Djetetov liječnik će propisati abakavir i zidovudin samo ako Vaše dijete ne može uzimati druge NRTIe.
At steady state, there was a significant induction of CYP 1A2 and a slight induction on CYP 2C9.
U stanju dinamičke ravnoteže, uočena je značajna indukcija CYP 1A2 i blaga indukcija CYP 2C9.
The black printing ink contains propylene glycol, black iron oxide, polyvinyl acetate phthalate, macrogol and ammonium hydroxide.
Crna tinta za označavanje kapsule sadrži propilenglikol, crni željezov oksid, poli(vinilacetat) ftalat, makrogol i amonijev hidroksid.
It is unknown whether the combination of tipranavir with ritonavir might cause a larger increase in fluticasone exposure.
Nije poznato može li kombinacija tipranavira s ritonavirom izazvati veći porast izlaganja flutikazonu.
A significant decrease in plasma concentrations of atazanavir and a marked increase of tipranavir and ritonavir concentrations was observed when Aptivus, associated with low dose ritonavir, was coadministered with atazanavir (see section 4.5).
Značajno smanjenje koncentracija atazanavira u plazmi i izraženo povećanje koncentracija tipranavira i ritonavira primijećeno je kada je Aptivus s niskom dozom ritonavira istodobno primjenjivan s atazanavirom (vidjeti dio 4.5).
Loperamide 16 mg QD Loperamide Cmax ↓ 61% Loperamide AUC ↓ 51%
Loperamid 16 mg QD Loperamid Cmax ↓ 61% Loperamid AUC ↓ 51%
Fatal and non-fatal intracranial haemorrhage (ICH) have been reported in patients receiving tipranavir, many of whom had other medical conditions or were receiving concomitant medicinal products that may have caused or contributed to these events.
Fatalno i nefatalno intrakranijalno krvarenje (ICH) prijavljeno je u bolesnika na tipranaviru, od kojih su mnogi imali druga medicinska stanja ili su istodobno dobivali lijekove koji su možda izazvali ili doprinijeli ovim događajima.
Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir in this study.
Nuspojave u smislu mučnine, omaglice, hipotenzije i sinkope primijećene su nakon istodobne primjene trazodona i ritonavira u ovom ispitivanju.
High density polyethylene (HDPE) bottle with two-piece child-resistant closure (outer and inner shell polypropylene, with a pulpboard/aluminium liner).
Boca od polietilena visoke gustoće (HDPE) s dvodijelnim sigurnosnim zatvaračem za djecu (vanjski i unutarnji dio - polipropilen, s celuloznim/aluminijskim zaštitnim pokrovom).
Aptivus oral solution is supplied in amber glass bottles containing 95 ml of oral solution.
Aptivus oralna otopina u staklenim bocama boje jantara s 95 ml oralne otopine.
Carbamazepine induces CYP3A4.
Karbamazepin inducira CYP3A4.
Key efficacy results at 48 weeks for patients 12 - 18 years of age who took capsule Endpoint
Ključni rezultati djelotvornosti na kraju 48 tjedana liječenja za bolesnike 12 - 18 godina starosti koji su uzimali kapsule
In a study comparing 9 patients with mild (Child-Pugh A) hepatic impairment to 9 controls, the single and multiple dose exposure of tipranavir and ritonavir were increased in patients with hepatic impairment but still within the range observed in clinical studies.
U ispitivanju koje je uspoređivalo 9 bolesnika s blagim (Child-Pugh A) oštećenjem jetre s 9 kontrolnih ispitanika, izloženost tipranaviru s ritonavirom nakon jednokratne i višekratne primjene bila je veća u bolesnika s oštećenjem jetre, ali još uvijek unutar raspona primijećenog u kliničkim ispitivanjima.
How to store Aptivus
Kako čuvati Aptivus
The mean steady-state trough concentration prior to the morning dose was 41.6 ± 24.3 µM for female patients and 35.6 ± 16.7 µM for male patients.
Prosječne najniže koncentracije u stanju ravnoteže (na kraju doznog intervala) prije jutarnje doze bile su 41,6 ± 24,3 µM u žena i 35,6 ± 16,7 µM u muškaraca.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE/IMMEDIATE PACKAGING
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU BOCA/UNUTARNJE PAKIRANJE
Dose ritonavir (mg)
Doza ritonavira (mg)
The Summary of Product Characteristics of ritonavir must therefore be consulted prior to initiation of therapy with Aptivus (especially as regards the contraindications, warnings and undesirable effects sections).
Stoga se prije početka liječenja Aptivusom mora pogledati Sažetak opisa svojstava lijeka za ritonavir (osobito dijelove o kontraindikacijama, upozorenjima i nuspojavama).
Your child will always have to take Aptivus in combination with other antiretroviral medicines.
Vaše dijete će uvijek morati uzimati Aptivus u kombinaciji s drugim antiretrovirusnim lijekovima.
Carbamazepine should be used with caution in combination with Aptivus, co-administered with low dose ritonavir.
Karbamazepin se primjenjuje s oprezom u kombinaciji s Aptivusom uz nisku dozu ritonavira.
Drugs by therapeutic area
Lijekovi po terapijskim područjima
The capsule shell contains gelatin, red iron oxide, propylene glycol, purified water, ‘sorbitol special-glycerin blend' (d-sorbitol, 1,4 sorbitan, mannitol and glycerin) and titanium dioxide.
Ovojnica kapsule sadrži želatinu, crveni željezov oksid, propilenglikol, pročišćenu vodu, mješavinu posebnog sorbitola s glicerinom (d-sorbitol, 1,4 sorbitan, manitol i glicerin) i titanijev dioksid.